Skip to main content
SpringerLink
Log in

Staging and Treatment. II-7. Overview of Treatment of Rectal Cancer

  • Chapter
  • First Online:
Gastrointestinal Cancer

  • 388 Accesses

Abstract

Radiotherapy is a local treatment and is commonly used as an adjuvant treatment before or after surgery for rectal cancer with a high probability of recurrence, that is, stage II or III. In the case of distant metastasis that can be resected even in stage IV, adjuvant radiation therapy can be performed and can be used to prevent recurrence after local excision of stage I cancer or as a first-line treatment when surgery is impossible or difficult. In addition, if surgery to preserve anal function is difficult due to the location or size of the tumor, radiation therapy before surgery can reduce the extent of the tumor and preserve the anus.

Sun Young Ma is the lead author of this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80(1):21–9.

    Article  CAS  PubMed  Google Scholar 

  2. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358(9290):1291–304.

    Article  Google Scholar 

  3. Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol. 2003;42:476–92.

    Article  PubMed  Google Scholar 

  4. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, BeartKubista RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–15.

    Article  CAS  PubMed  Google Scholar 

  5. Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol. 1988;13(4):245–52.

    Article  CAS  PubMed  Google Scholar 

  6. Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000;92(5):388–96.

    Article  CAS  PubMed  Google Scholar 

  7. Cedermark B, Dahlberg M, Glimelius B, Påhlman L, Rutqvist LE, Wilking N. Swedish rectal cancer trial: improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7.

    Article  CAS  PubMed  Google Scholar 

  8. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644–50.

    Article  PubMed  Google Scholar 

  9. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–646.

    Google Scholar 

  10. van Gijn W, Marijnen CAM, Nagtegaal ID, Kranenbarg EMK, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.

    Article  PubMed  Google Scholar 

  11. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.

    Article  PubMed  Google Scholar 

  12. Jean-François B, Laurence C, Gilles C, Laurent M, Philippe M, Ljiljana RJ, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.

    Article  Google Scholar 

  13. Ceelen WP, Van Nieuwenhove Y, Fierens K, Pattyn P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2009;(1):CD006041.

    Google Scholar 

  14. Fiorica F, Cartei F, Licata A, Enea M, Ursino S, Colosimo C, et al. Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev. 2010;36:539–49.

    Article  CAS  PubMed  Google Scholar 

  15. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al.; Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740.

    Google Scholar 

  16. Park J, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer. 2011;117(16):3703–12.

    Article  CAS  PubMed  Google Scholar 

  17. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373(9666):811–20.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Song JH, Jeong JU, Lee JH, Kim SH, Cho HM, Um JW, et al.; Korean Clinical Practice Guideline for Colon and Rectal Cancer Committee. Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II-III resectable rectal cancer: a meta-analysis of randomized controlled trials. Radiat Oncol. 2017;35(3):198–207.

    Google Scholar 

  19. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.

    Article  CAS  PubMed  Google Scholar 

  20. NCCN clinical practice guidelines in oncology (NCCN guidelines), rectal cancer. Version 2. 2021.

    Google Scholar 

  21. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.

    Article  CAS  PubMed  Google Scholar 

  22. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-Tasman radiation oncology group trial 01.04. J Clin Oncol. 2012;30:3827–33.

    Article  PubMed  Google Scholar 

  23. Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18(3):336–46.

    Article  PubMed  Google Scholar 

  24. Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773–80.

    Article  PubMed  Google Scholar 

  25. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501–13.

    Article  PubMed  Google Scholar 

  26. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al.; WWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537.

    Google Scholar 

  27. Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5(4):e185896.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Sanford NN, Dee EC, Ahn C, Kazmi SA, Beg MS, Folkert MR, rt al. Recent trends and overall survival of young versus older adults with stage II to III rectal cancer treated with and without surgery in the United States, 2010-2015. Am J Clin Oncol. 2020;43(10):694–700.

    Article  PubMed  Google Scholar 

  29. Wo JY, Anker CJ, Ashman JB, Bhadkamkar NA, Bradfield L, Chang DT, et al. Radiation therapy for rectal cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2021;11:13–25.

    Article  PubMed  Google Scholar 

  30. Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017;390(10093):469–79.

    Article  PubMed  Google Scholar 

  31. Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, van Meerten E, et al. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study. JAMA Surg. 2019;154:47–54.

    Article  PubMed  Google Scholar 

  32. Creavin B, Ryan E, Martin ST, Hanly A, O’Connell PR, Sheahan K, et al. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. Br J Cancer. 2017;116:169–74.

    Article  CAS  PubMed  Google Scholar 

  33. Habr-Gama A, Lynn PB, Jorge JM, São Julião GP, Proscurshim I, Gama-Rodrigues J, et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum. 2016;59:264–9.

    Article  PubMed  Google Scholar 

  34. Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65:1129–42.

    Article  PubMed  Google Scholar 

  35. Valentini V, Gambacorta MA, Barbaro B, Chiloiro G, Coco C, Das P, et al. International consensus guidelines on Clinical Target Volume delineation in rectal cancer. Radiother Oncol. 2016;120:195–201.

    Article  PubMed  Google Scholar 

  36. Gallagher MJ, Brereton HD, Rostock RA, Zero JM, Zekoski DA, Poyss LF, et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys. 1986;12(9):1565–73.

    Article  CAS  PubMed  Google Scholar 

  37. Nuyttens JJ, Robertson JM, Yan D, Martinez A. The position and volume of the small bowel during adjuvant radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2001;51(5):1271–80.

    Article  CAS  PubMed  Google Scholar 

  38. Dröge LH, Weber HE, Guhlich M, Leu M, Conradi LC, Gaedcke J, et al. Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3-D conformal radiotherapy. BMC Cancer. 2015;15:750.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Regnier A, Ulbrich J, Münch S, Oechsner M, Wilhelm D, Combs SE, et al. Comparative analysis of efficacy, toxicity, and patient-reported outcomes in rectal cancer patients undergoing preoperative 3-D conformal radiotherapy or VMAT. Front Oncol. 2017;7:225.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Stuyck C, Wegge M, Bulens P, Joye I, Haustermans K, et al. Moderate dose escalation with volumetric modulated arc therapy improves outcome in rectal cancer. Acta Oncol. 2017;56:1501–6.

    Article  PubMed  Google Scholar 

  41. Ng SY, Colborn KL, Cambridge L, Hajj C, Yang TJ, Wu AJ, et al. Acute toxicity with intensity modulated radiotherapy versus 3-dimensional conformal radiotherapy during preoperative chemoradiation for locally advanced rectal cancer. Radiother Oncol. 2016;121:252–7.

    Article  PubMed  Google Scholar 

  42. Wee CW, Kang HC, Wu HG, Chie EK, Choi N, Park JM, et al. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a metaanalysis and pooled-analysis of acute toxicity. Jpn J Clin Oncol. 2018;48:458–66.

    Article  PubMed  Google Scholar 

  43. Yu M, Jang HS, Jeon DM, Cheon GS, Lee HC, Chung MJ, et al. Dosimetric evaluation of tomotherapy and four-box field conformal radiotherapy in locally advanced rectal cancer. Radiat Oncol J. 2013;31(4):252–9.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Haddock MG. Intraoperative radiation therapy for colon and rectal cancers: a clinical review. Radiat Oncol. 2017;12(1):11.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Nakfoor BM, Willett CG, Shellito PC, Kaufman DS, Daly WJ. The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. Ann Surg. 1998;228(2):194–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Mathis KL, Nelson H, Pemberton JH, Haddock MG, Gunderson LL. Unresectable colorectal cancer can be cured with multimodality therapy. Ann Surg. 2008;248(4):592–8.

    Article  PubMed  Google Scholar 

  47. Lange MM, Maas CP, Marijnen CA, Wiggers T, Rutten HJ, Kranenbarg EK, et al. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg. 2008;95(8):1020–8.

    Article  CAS  PubMed  Google Scholar 

  48. Vironen JH, Kairaluoma M, Aalto AM, Kellokumpu IH. Impact of functional results on quality of life after rectal cancer surgery. Dis Colon Rectum. 2006;49:568–78.

    Article  PubMed  Google Scholar 

  49. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B, Swedish Rectal Cancer Trial Group. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish rectal cancer trial. J Clin Oncol. 2005;23:8697–705.

    Article  PubMed  Google Scholar 

  50. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23(25):6199–206.

    Article  CAS  PubMed  Google Scholar 

  51. McGough C, Baldwin C, Frost G, Andreyev HJ. Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy. Br J Cancer. 2004;90(12):2278–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Wiltink LM, Nout RA, Fiocco M, Meershoek-Klein Kranenbarg E, Jürgenliemk-Schulz IM, Jobsen JJ, et al. No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials. J Clin Oncol. 2015;33(15):1640–6.

    Article  PubMed  Google Scholar 

  53. Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23(9):1847–58.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea (Republic of)

    Hoon Jai Chun

  2. Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea (Republic of)

    Seun Ja Park

  3. Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Kyonggi-do, Korea (Republic of)

    Yun Jeong Lim

  4. Department of Internal Medicine, Yonsei University Severance Hospital, Seoul, Korea (Republic of)

    Si Young Song

Authors
  1. Hoon Jai Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seun Ja Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun Jeong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Si Young Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chun, H.J., Park, S.J., Lim, Y.J., Song, S.Y. (2023). Staging and Treatment. II-7. Overview of Treatment of Rectal Cancer. In: Gastrointestinal Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-99-0815-8_40

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-0815-8_40

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-0814-1

  • Online ISBN: 978-981-99-0815-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation